Sejauh manakah kecekapan dan keberkesanan perkhidmatan pos di Shah Alam setelah diswastakan. Satu tinjauan / Ani Awang ... [et al.]

Penswastaan perkhidmatan pos adalah suatu perkara yang tidak asing lagi kepada mas'yarakat Malaysia dalam tempoh lebih dua tahun dalam usaha untuk meningkatkan kecekapan dan untuk memberikan perkhidmatan yang terbaik kepada orangramai

Hot water extract from saccharomyces cerevisiae scavenges dpph and reduces senescence associated β-Galactosidase (Sa-β-Gal) in human dermal fibroblasts

Extracts from Saccharomyces cerevisiae are incorporated in a lot of cosmetic products on the market, but the benefits of the extracts lack scientific reports. We tested the toxicity and anti-senescent activity of an extract from S. cerevisiae on an in vitro model, the human dermal fibroblast (HDF) cell culture. We chronicled the development of the extraction method and the subsequent biochemical assays. We used two extraction methods which were hot water extraction and rapid spin. The optimum duration and growth phase to harvest S. cerevisiae were determined by 2,2-diphenyl-1- picrylhydrazyl (DPPH) assay, which also proved that the extracts exhibited antioxidant activity. Hot water extract showed a higher antioxidant activity, and not toxic to HDF. When subjected to senescence-associated β-galactosidase (SA-β-al) assay, the hot water extract significantly reduced the expression of SA-β-Gal in pre-senescent (passage 20, 30 < population doubling 50) HDF. In conclusion, S. cerevisiae hot water extract possessed antioxidant activity by scavenging DPPH, and anti-senescent activity by reducing the expression of SA-β-Gal in pre-senescent and senescent HDF

Tocotrienol rich fraction supplementation improved lipid profile and oxidative status in healthy older adults: A randomized controlled study

<p>Abstract</p> <p>Background</p> <p>Vitamin E supplements containing tocotrienols are now being recommended for optimum health but its effects are scarcely known. The objective was to determine the effects of Tocotrienol Rich Fraction (TRF) supplementation on lipid profile and oxidative status in healthy older individuals at a dose of 160 mg/day for 6 months.</p> <p>Methods</p> <p>Sixty-two subjects were recruited from two age groups: 35-49 years (n = 31) and above 50 years (n = 31), and randomly assigned to receive either TRF or placebo capsules for six months. Blood samples were obtained at 0, 3^rdand 6^thmonths.</p> <p>Results</p> <p>HDL-cholesterol in the TRF-supplemented group was elevated after 6 months (p < 0.01). Protein carbonyl contents were markedly decreased (p < 0.001), whereas AGE levels were lowered in the > 50 year-old group (p < 0.05). Plasma levels of total vitamin E particularly tocopherols were significantly increased in the TRF-supplemented group after 3 months (p < 0.01). Plasma total tocotrienols were only increased in the > 50 year-old group after receiving 6 months of TRF supplementation. Changes in enzyme activities were only observed in the > 50 year-old group. SOD activity was decreased after 3 (p < 0.05) and 6 (p < 0.05) months of TRF supplementation whereas CAT activity was decreased after 3 (p < 0.01) and 6 (p < 0.05) months in the placebo group. GPx activity was increased at 6 months for both treatment and placebo groups (p < 0.05).</p> <p>Conclusion</p> <p>The observed improvement of plasma cholesterol, AGE and antioxidant vitamin levels as well as the reduced protein damage may indicate a restoration of redox balance after TRF supplementation, particularly in individuals over 50 years of age.</p

Characterization of potential probionts from blue swimming crab Portunus pelagicus and its antagonistic activity against Vibrio harveyi

The aim of this study was to isolate local bacteria as potential probiont in controlling the growth of pathogenic Vibrio harveyi. Eleven potential bacteria were successfully isolated from the haemolymph of four healthy Portunus pelagicus. All of the isolates were identified as Bacillus amyloliquefaciens by series of biochemical test using triple sugar ion test, oxidase and catalase test, followed by Internal Transcribe Spacer (ITS) gene sequence analysis. This isolate was able to inhibit the growth of V. harveyi in in-vitro screening assay by using well diffusion assay with the strong antagonistic activity from 7 to 16 mm. The potential strains at 108 CFU/ml showed highest inhibition response towards V. harveyi after co-cultured for 48 hr. The isolates produced four major extracellular enzymes which were amylase, protease, gelatinase and lipase and able to form biofilm after 24 hr of cultured. Thus, B. amyloliquefaciens showed important characteristics as probiotic which worth to be carried out for in vivo challenge assay

Smart Mobility Cities: Connecting Bristol and Kuala Lumpur project report

Financed by the British Council Institutional Links program this Smart Mobility Cities project has opened a fascinating window on a journey of discovery linking Bristol and Kuala Lumpur. This journey was in part directed towards the realisation of Smart Mobility solutions to the socio-economic and environmental challenges of global urbanisation. Beyond this, the journey was also concerned to strengthen research and innovation partnerships between the UK and the emerging knowledge economy of Malaysia, enabling UK social scientists to collaborate on challenging global issues with international researchers and vice versa. This Smart Mobility Cities project report presents innovative, creative and yet fully practical solutions for these societal challenges. Solutions that explore a range of opportunities, whichinclude those arising from new urban governance requirements, and which are in-line with visions for sustainable urban mobility.These Smart Mobility solutions have arisen from intensive co-design and co-creation engagement with a diversity of stakeholders. Research co-production has linked the principal university partners of the University of the West of England (UWE), Bristol, and Taylor’sUniversity, Kuala Lumpur, together with the Malaysia Institute of Transport (MITRANS), Universiti Teknologi Mara, and the University Sains Malaysia (USM) in intensive engagement with stakeholder interests in both UK and Malaysia over a two-year period

An overview of biomass thermochemical conversion technologies in Malaysia

The rising pressure on both cleaner production and sustainable development have been the main driving force that pushes mankind to seek for alternative greener and sustainable feedstocks for chemical and energy production. The biomass ‘waste-to-wealth’ concept which convert low value biomass into value-added products which contain high economic potential, have attracted the attentions from both academicians and industry players. With a tropical climate, Malaysia has a rich agricultural sector and dense tropical rainforest, giving rise to abundance of biomass which most of them are underutilized. Hence, the biomass ‘waste-to-wealth’ conversion through various thermochemical conversion technologies and the prospective challenges towards commercialization in Malaysia are reviewed in this paper. In this paper, a critical review about the maturity status of the four most promising thermochemical conversion routes in Malaysia (i.e. gasification, pyrolysis, liquefaction and hydroprocessing) is given. The current development of thermochemical conversion technologies for biomass conversion in Malaysia is also reviewed and benchmarked against global progress. Besides, the core technical challenges in commercializing these green technologies are highlighted as well. Lastly, the future outlook for successful commercialization of these technologies in Malaysia is included

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.

BACKGROUND World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coronavirus disease 2019 (Covid-19). METHODS We randomly assigned inpatients with Covid-19 equally between one of the trial drug regimens that was locally available and open control (up to five options, four active and the local standard of care). The intention-to-treat primary analyses examined in-hospital mortality in the four pairwise comparisons of each trial drug and its control (drug available but patient assigned to the same care without that drug). Rate ratios for death were calculated with stratification according to age and status regarding mechanical ventilation at trial entry. RESULTS At 405 hospitals in 30 countries, 11,330 adults underwent randomization; 2750 were assigned to receive remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including 651 to interferon plus lopinavir), and 4088 to no trial drug. Adherence was 94 to 96% midway through treatment, with 2 to 6% crossover. In total, 1253 deaths were reported (median day of death, day 8; interquartile range, 4 to 14). The Kaplan-Meier 28-day mortality was 11.8% (39.0% if the patient was already receiving ventilation at randomization and 9.5% otherwise). Death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence interval [CI], 0.81 to 1.11; P = 0.50), in 104 of 947 patients receiving hydroxychloroquine and in 84 of 906 receiving its control (rate ratio, 1.19; 95% CI, 0.89 to 1.59; P = 0.23), in 148 of 1399 patients receiving lopinavir and in 146 of 1372 receiving its control (rate ratio, 1.00; 95% CI, 0.79 to 1.25; P = 0.97), and in 243 of 2050 patients receiving interferon and in 216 of 2050 receiving its control (rate ratio, 1.16; 95% CI, 0.96 to 1.39; P = 0.11). No drug definitely reduced mortality, overall or in any subgroup, or reduced initiation of ventilation or hospitalization duration. CONCLUSIONS These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay. (Funded by the World Health Organization; ISRCTN Registry number, ISRCTN83971151; ClinicalTrials.gov number, NCT04315948.)